Haemate

Haemate is a prescription injectable solution that contains human coagulation factor VIII and human von Willebrand factor. It is supplied as a sterile liquid for intravenous administration, with the specific strength determined by the manufacturer. The product is classified as a hemostatic agent and is used in the European market to replace deficient clotting proteins in patients with certain bleeding disorders through targeted therapy under medical supervision.

Haemate is indicated for the management of bleeding episodes and perioperative prophylaxis in patients with specific inherited clotting deficiencies.

- Replacement therapy for hemophilia A patients with factor VIII deficiency. - Treatment of von Willebrand disease types 1, 2, and 3 to restore von Willebrand factor activity. - Control of acute bleeding episodes such as joint or muscle hemorrhages. - Surgical or dental procedure prophylaxis to maintain hemostasis. - Long‑term secondary prophylaxis in individuals with severe hemophilia A. - Adjunctive therapy in combination with other clotting factor concentrates when individualized dosing is required.

The safety profile of Haemate reflects the typical reactions observed with plasma‑derived clotting factor concentrates.

Common: - Mild infusion site erythema or swelling. - Transient headache or fatigue. - Low‑grade fever within 24 hours of administration. - Transient nausea or vomiting. - Mild joint stiffness lasting less than 48 hours. - Mild increase in liver enzymes (ALT/AST) that resolves spontaneously.

Serious: - Development of inhibitors (antibodies) against factor VIII or von Willebrand factor. - Allergic reactions ranging from urticaria to anaphylaxis. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Hemolytic reactions due to contaminant proteins. - Renal impairment exacerbated by volume overload. - Severe hypersensitivity leading to bronchospasm or hypotension.

When prescribing Haemate, clinicians should consider several precautionary measures to ensure safe and effective use.

- Verify the patient’s baseline factor VIII and von Willebrand factor levels before initiating therapy. - Screen for a history of inhibitor development or previous allergic reactions to plasma‑derived products. - Monitor for signs of thrombosis, especially in patients with cardiovascular risk factors. - Assess renal and hepatic function periodically during long‑term treatment. - Use the lowest effective dose to maintain hemostasis and reduce exposure. - Counsel patients on proper storage, handling, and disposal of the injectable solution. - Document any adverse events promptly in the patient’s medical record.

Haemate may interact with other medicines that affect coagulation or the immune system; awareness of these interactions helps optimize therapy.

Avoid: - Concomitant use of other plasma‑derived clotting factor concentrates without specialist guidance. - Administration of high‑dose pro‑coagulant agents (e.g., recombinant activated factor VII) that could increase thrombotic risk. - Concurrent use of desmopressin (DDAVP) without monitoring, as it may cause additive hemostatic effect.

Use with caution: - Antifibrinolytic agents such as tranexamic acid, which may enhance clot stability but require monitoring. - Immunosuppressive drugs that could alter inhibitor development, including rituximab or cyclophosphamide. - Certain antibiotics (e.g., vancomycin) that have been associated with rare hypersensitivity reactions when combined with plasma products.